

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A ~~vaccine against the cold-water disease in fish,~~  
pharmaceutically administrable composition comprising, ~~as an effective component,~~  
inactivated cells of *Flavobacterium psychrophilum* ~~psychrophilum~~ in a logarithmic growth  
phase and at least one pharmaceutically acceptable carrier or adjuvant ~~or components of the~~  
cells.

2. (Currently Amended) A ~~vaccine~~ pharmaceutically administrable composition for  
~~the cold-water disease in fish,~~ comprising components of inactivated cells of *Flavobacterium*  
~~psychrophilum~~ *Flavobacterium psychrophilum* in a logarithmic growth phase ~~or components~~  
~~of the cells~~ and at least one pharmaceutically acceptable carrier or adjuvant, wherein said  
components comprises cell membrane components, vesicles, and/or secretory products.

3. (Currently Amended) A method for preventing the cold-water disease in fish,  
comprising administering an effective dosage of ~~inactivated cells of Flavobacterium~~  
~~psychrophilum in a logarithmic growth phase or components of the cells~~ the composition  
according to Claim 1 to a fish in need thereof to thus prevent cold-water disease.

4. (New) A method for preventing the cold-water disease in fish, comprising  
administering an effective dosage of the composition according to Claim 2 to a fish in need  
thereof to thus prevent cold-water disease.

5. (New) The composition according to Claim 1, wherein said *Flavobacterium*  
*psychrophilum* in a logarithmic growth phase are isolated from a growth culture by

centrifugation or filtration.

6. (New) The composition according to Claim 1, wherein said *Flavobacterium psychrophilum* in a logarithmic growth phase are inactivated by heat treatment.

7. (New) The composition according to Claim 1, wherein said *Flavobacterium psychrophilum* in a logarithmic growth phase are inactivated by formalin treatment.

8. (New) The composition according to Claim 1, wherein said pharmaceutically acceptable carrier is a liquid carrier.

9. (New) The composition according to Claim 8, wherein said liquid carrier is water or physiological saline.

10. (New) The composition according to Claim 1, wherein said pharmaceutically acceptable carrier is a solid carrier.

11. (New) The composition according to Claim 10, wherein said solid carrier is talc or sucrose.

12. (New) The composition according to Claim 2, wherein said *Flavobacterium psychrophilum* in a logarithmic growth phase are isolated from a growth culture by centrifugation or filtration.

13. (New) The composition according to Claim 2, wherein said *Flavobacterium psychrophilum* in a logarithmic growth phase are inactivated by heat treatment.

14. (New) The composition according to Claim 2, wherein said *Flavobacterium psychrophilum* in a logarithmic growth phase are inactivated by formalin treatment.

15. (New) The composition according to Claim 2, wherein said pharmaceutically acceptable carrier is a liquid carrier.

16. (New) The composition according to Claim 15, wherein said liquid carrier is water or physiological saline.

17. (New) The composition according to Claim 2, wherein said pharmaceutically acceptable carrier is a solid carrier.

18. (New) The composition according to Claim 17, wherein said solid carrier is talc or sucrose.

19. (New) The method according to Claim 3, wherein said fish in need thereof is an adult fish.

20. (New) The method according to Claim 3, wherein said fish in need thereof is selected from the group consisting of ayu, crucian carp, salmon, yamame, rainbow trout, and silver trout.

21. (New) The method according to Claim 3, wherein said effective dosage ranges from 1 mg to 5 g per 1 kg of body weight of said fish in need thereof.

22. (New) The method according to Claim 3, wherein said administering is once to ten times per day.

23. (New) The method according to Claim 3, wherein said administering is every day.

24. (New) The method according to Claim 3, wherein said administering is at an interval of one or two days.

25. (New) The method according to Claim 4, wherein said fish in need thereof is an adult fish.

26. (New) The method according to Claim 4, wherein said fish in need thereof is selected from the group consisting of ayu, crucian carp, salmon, yamame, rainbow trout, and silver trout.

27. (New) The method according to Claim 4, wherein said effective dosage ranges from 1 mg to 5 g per 1 kg of body weight of said fish in need thereof.

28. (New) The method according to Claim 4, wherein said administering is once to ten times per day.

29. (New) The method according to Claim 4, wherein said administering is every day.

30. (New) The method according to Claim 4, wherein said administering is at an interval of one or two days.

SUPPORT FOR THE AMENDMENTS

Claims 1-3 have been amended.

Claims 4-30 have been added.

The amendment of Claims 1-3 is supported by the original Claims 1-3 and pages 7-8 of the specification. New Claims 4-30 are supported by the specification at pages 5-8.

In addition, the specification has been amended to capitalize the tradenames and to insert the corresponding generic equivalent.

No new matter is believed to have been entered by the present amendments.